MaxCyte Q4 2025 Earnings Call Transcript: Revenue Down, New Product Launch, and Integration of SecurDx Acquisition

MaxCyte (MXCT) reported $33 million in total revenue for FY25, including $29.6 million of core revenue and $3.4 million of strategic platform license program-related revenue. The company grew its instrument installed base to 857 and launched a new product, Xpert DTX, a modular 96-well electroporation platform for research and drug discovery applications. MaxCyte faced headwinds in 2025 due to program consolidation and rationalization across some SPL customers.